Ardmore Shipping Logo
MHY0207T1001

Ardmore Shipping

Ins Portfolio
60% Chancen, 40% Gelassenheit. Aktien und Anleihen in einem LifeStrategy ETF. Jetzt entdecken
Anzeige

Kurse werden geladen...

Prognose

Das durchschnittliche Kursziel der Analysten beträgt +13,30(+58,71%). Der Median liegt bei +14,90(+77,80%).

Kaufen
  11
Halten
  4
Verkaufen
  0

Scoring-Modelle

Dividenden-Strategie8 / 15
HGI-Strategie6 / 18
Levermann-Strategie4 / 13
Powered byaktien.guide

News


  • Ascletis Announces Poster Presentations on the Study Results of ASC30 and ASC47 at the 85th Scientific Sessions of American Diabetes Association (ADA)

    HONG KONG , June 8, 2025 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") announces that poster presentations on preliminary studies of its oral small molecule GLP-1 Receptor (GLP-1R) agonist ASC30 and adipose-targeted, muscle-preserving weight loss drug candidate ASC47 will be presented at the 85th Scientific Sessions of American Diabetes Association (ADA) in Chicago, U.S. Details of the Poster Presentations Poster Number: 750-P Abstract Title: ASC30, an Oral GLP-1R Biased Small Molecule Agonist in Participants with Obesity—A First-in-Human Single Ascending Dose Study Session Type: General Poster Session Location: Poster Hall (Hall F1) Presentation Time: Sunday Jun 22, 2025 12:30 PM - 1:30 PM (Chicago Time), i.e., Monday Jun 23, 2025 1:30 AM - 2:30 AM (Beijing Time) Poster Number: 847-P Abstract Title: ASC47, a Muscle-Preserving Weight Loss Drug Candidate for Obesity, in Combination with Semaglutide, Demonstrated Superior Weight Loss to Semaglutide Monotherapy in a Preclinical Model Session Type: General Poster Session Location: Poster Hall (Hall F1) Presentation Time: Sunday Jun 22, 2025 12:30 PM - 1:30 PM (Chicago Time), i.e.» Mehr auf prnewswire.com


  • Ascletis Announces Phase III Trial of Denifanstat (ASC40), a First-in-Class, Once-Daily Oral FASN Inhibitor for Acne, Meets All Endpoints

    Denifanstat (ASC40), a once-daily oral fatty acid synthase (FASN) inhibitor, demonstrated statistically significant and clinically meaningful improvement compared to placebo in all primary, key secondary, and secondary endpoints Denifanstat demonstrated a favorable safety and tolerability profile Denifanstat was 98% and 178% more effective than U.S. Food and Drug Administration (FDA)-approved sarecycline and doxycycline with regard to placebo-adjusted percent treatment success, respectively, 18.6% for denifanstat versus 9.4% for sarecycline, 18.6% versus 6.7% for doxycycline Denifanstat was 60% more effective than FDA-approved clascoterone cream with regard to placebo-adjusted percent treatment success, 18.6% for denifanstat versus 11.6% for clascoterone cream, respectively The exceptional efficacy of denifanstat coupled with its favorable safety profile in the Phase III trial provides a potential major break-through for the treatment of acne HONG KONG , June 3, 2025 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") announces today that denifanstat (ASC40), a first-in-class, once-daily oral small molecule fatty acid synthase (FASN) inhibitor, meets all primary, key secondary, and secondary endpoints in the Phase III clinical trial for the treatment of moderate to severe acne vulgaris (NCT06192264). The Phase III clinical trial was a randomized, double-blind, placebo-controlled, multicenter clinical trial in China to evaluate the safety and efficacy of denifanstat once-daily oral tablet in 480 patients with moderate to severe acne vulgaris.» Mehr auf prnewswire.com


  • Investors Heavily Search Ardmore Shipping Corporation (ASC): Here is What You Need to Know

    Recently, Zacks.com users have been paying close attention to Ardmore Shipping (ASC). This makes it worthwhile to examine what the stock has in store.» Mehr auf zacks.com

Dividenden

Alle Kennzahlen
In 2025 hat Ardmore Shipping bereits +0,0732 Dividende ausgeschüttet. Die letzte Dividende wurde im März gezahlt.

Unternehmenszahlen

Im letzten Quartal hatte Ardmore Shipping einen Umsatz von +68,40 Mio und ein Nettoeinkommen von +5,78 Mio
(EUR)März 2025
YOY
Umsatz+68,40 Mio30,56%
Bruttoeinkommen+19,42 Mio56,02%
Nettoeinkommen+5,78 Mio84,10%
EBITDA+13,70 Mio69,98%

Fundamentaldaten

MetrikWert
Marktkapitalisierung
+342,87 Mio
Anzahl Aktien
40,62 Mio
52 Wochen-Hoch/Tief
+20,30 - +7,29
Dividendenrendite
+10,41%
Dividenden TTM
+0,88
Nächste Dividende
+0,0438
Beta
0,01
KGV (PE Ratio)
+4,17
KGWV (PEG Ratio)
0,14
KBV (PB Ratio)
+0,61
KUV (PS Ratio)
+1,31

Unternehmensprofil

Ardmore Shipping Corporation befasst sich mit dem weltweiten Seetransport von Erdölprodukten und Chemikalien. Am 15. Februar 2022 betrieb das Unternehmen eine Flotte von 25 Doppelhüllen-Produkt- und Chemikalientankern. Es bedient Ölkonzerne, Ölgesellschaften, Öl- und Chemikalienhändler, Chemieunternehmen und Pooling-Dienstleister. Das Unternehmen wurde im Jahr 2010 gegründet und hat seinen Sitz in Pembroke, Bermuda.

Name
Ardmore Shipping
CEO
Gernot Ruppelt
SitzPembroke,
Irland
Website
Industrie
Seetransport
Börsengang
Mitarbeiter56

Ticker Symbole

BörseSymbol
NYSE
ASC
Frankfurt
A61.F
Düsseldorf
A61.DU
München
A61.MU
🍪

Parqet nutzt Cookies.Erfahre Mehr